Sunesis Pharmaceuticals (SNSS) 2.28 $SNSS
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments
Marketwired - Tue Feb 03, 8:15AM CST
Streetwise Reports/The Life Sciences Report released notes from the 2015 Small-Cap Biotech Watchlist panel discussion, which occurred at the Biotech Showcase in San Francisco on January 13. The Watchlist companies selected by top sector analysts include Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The panel focused on companies they believe should see significant gains in 2015.
CANF: 3.85 (+0.05), SNSS: 2.28 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 8:07AM CST
SID: 1.76 (+0.06), FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), SNSS: 2.28 (+0.01), NQ: 3.95 (-0.03), XOOM: 15.77 (+0.64)
Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.57 (+0.36), ARWR: 6.77 (+0.21), ACHN: 10.89 (-0.20), SNSS: 2.28 (+0.01), ARRY: 8.05 (+0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 8:10AM CST
GDP: 3.58 (+0.29), WATT: 9.43 (+0.01), MILL: 2.07 (+0.09), SNSS: 2.28 (+0.01), CYRN: 2.83 (+0.23), NQ: 3.95 (-0.03), LE: 35.84 (+0.19), TPLM: 5.68 (+0.06), ALLT: 9.15 (+0.02), YUM: 74.69 (-0.11)
Sunesis Pharma gets a big boost from Cantor
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 6:27AM CST
SNSS: 2.28 (+0.01)
Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting
GlobeNewswire - Mon Dec 08, 12:30PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The results will be presented today in an oral session titled "Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Drugs II" taking place from 10:30 AM to 12:00 PM PT at the 56 American Society of Hematology Annual Meeting in San Francisco, California. The presentation (abstract 385, Gateway Ballroom 103), titled "Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)," is available at www.sunesis.com.
SNSS: 2.28 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST
LGCY: 13.35 (+0.51), PFIE: 2.60 (-0.06), MCEP: 6.29 (+0.12), MDGN: 7.13 (-0.75), LQDT: 9.52 (+0.09), AXPW: 0.39 (-0.04), PRTK: 26.95 (+0.65), BSI: 2.97 (+0.02), DRIV: 25.99 (+0.06), CBST: 101.94 (+0.14), QTWW: 2.96 (-0.04), CALA: 16.11 (+0.62), MPO: 1.00 (-0.02), SNSS: 2.28 (+0.01), CTP: 6.53 (+0.13), LPX: 17.44 (+0.42), SAEX: 3.75 (+0.50), DRYS: 1.01 (+0.02), VPCO: 1.02 (+0.01), XLRN: 38.02 (+0.07)
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 90.70 (+0.93), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), SNSS: 2.28 (+0.01), AGIO: 118.55 (+0.11), BMY: 60.04 (+0.56), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Sunesis Spin Doctor Tiptoes Around Failed Leukemia Drug Trial
at The Street - Sun Dec 07, 4:28PM CST
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
SNSS: 2.28 (+0.01)
Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:30AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented on Tuesday, December 9, at 8:45 AM Pacific Time in the "Late Breaking Abstracts" session of the 56 American Society of Hematology Annual Meeting in San Francisco, California. The presentation (abstract LBA-6, North Building, Hall D), titled "Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)," will be available on the Sunesis website at www.sunesis.com following the ASH presentation.
SNSS: 2.28 (+0.01)
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
at The Street - Tue Dec 02, 10:00AM CST
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CYTR: 2.96 (+0.23), SNSS: 2.28 (+0.01), CTIC: 2.23 (-0.02), NVS: 102.20 (-0.17)
Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting
GlobeNewswire - Tue Dec 02, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9, 2014 at 10:30 AM Pacific Time to discuss the presentation of results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML), as well as an MD Anderson Cancer Center-sponsored Phase 1/2 study of vosaroxin and decitabine in newly diagnosed older patients with AML and high risk myelodysplastic syndrome, at the 56th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9 in San Francisco, California.
SNSS: 2.28 (+0.01)
Today In SA PRO: Monday, December 1
SA PRO Top Ideas - at Seeking Alpha - Tue Dec 02, 4:00AM CST
Top Idea: Cooper-Standard by Alpha Gen Capital: Long / Small-Cap / Auto Parts / GARP / Margin Expansion / Market Share Growth / Underfollowed / 40% Upside Top Idea: Home Loan Servicing Solutions by Moses Li, Mikhail Stepanov, and Shaun Raja:...
VTNR: 3.55 (+0.25), CPS: 54.36 (-0.13), SNSS: 2.28 (+0.01), LE: 35.84 (+0.19), HLSS: 16.15 (-0.14)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 2.13 (+0.18), AMRN: 1.18 (unch), JCP: 8.05 (+0.14), SNSS: 2.28 (+0.01), SWHC: 12.63 (-0.20)
Announcing This Week's Outstanding Performance Award Winners - New Capital And EnhydrisPECorp
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Dec 01, 4:00AM CST
Dear readers, Seeking Alpha has been paying contributors for exclusive content since 2011. We launched SA PRO two years ago, on the Monday after Thanksgiving 2012, with the dual aim of creating a premium subscription product for interested readers...
SNSS: 2.28 (+0.01), LE: 35.84 (+0.19)
Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology
GlobeNewswire - Mon Nov 24, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of results from the Company's REVEAL-1 (Response Evaluation of Vosaroxin in Elderly AmL) trial, a Phase 2 trial of single agent vosaroxin in previously untreated, poor-risk elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy, in the November 17, 2014 Online Version of Record of the British Journal of Haematology. The article, titled "REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukemia," is available online at http://onlinelibrary.wiley.com/doi/10.1111/bj...4/abstract.
SNSS: 2.28 (+0.01)
Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica
GlobeNewswire - Wed Nov 19, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the online publication of results from the Company's Phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) in the November 7, 2014 Ahead of Print issue of Haematologica. The article, titled "A Phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia," is available online at http://www.haematologica.org/content/early/recent.
SNSS: 2.28 (+0.01)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 101.90 (+1.10), FB: 75.74 (-0.49), GERN: 3.03 (unch), DNDN: 0.13 (-0.02), SNSS: 2.28 (+0.01), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), GRPN: 7.97 (+0.51), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), RFMD: 16.59 (-0.35)
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:25AM CST
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 391.66 (-0.45), SNSS: 2.28 (+0.01), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments
Marketwired - Tue Feb 03, 8:15AM CST
Streetwise Reports/The Life Sciences Report released notes from the 2015 Small-Cap Biotech Watchlist panel discussion, which occurred at the Biotech Showcase in San Francisco on January 13. The Watchlist companies selected by top sector analysts include Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The panel focused on companies they believe should see significant gains in 2015.
CANF: 3.85 (+0.05), SNSS: 2.28 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 8:07AM CST
SID: 1.76 (+0.06), FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), SNSS: 2.28 (+0.01), NQ: 3.95 (-0.03), XOOM: 15.77 (+0.64)
Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.57 (+0.36), ARWR: 6.77 (+0.21), ACHN: 10.89 (-0.20), SNSS: 2.28 (+0.01), ARRY: 8.05 (+0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 8:10AM CST
GDP: 3.58 (+0.29), WATT: 9.43 (+0.01), MILL: 2.07 (+0.09), SNSS: 2.28 (+0.01), CYRN: 2.83 (+0.23), NQ: 3.95 (-0.03), LE: 35.84 (+0.19), TPLM: 5.68 (+0.06), ALLT: 9.15 (+0.02), YUM: 74.69 (-0.11)
Sunesis Pharma gets a big boost from Cantor
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 6:27AM CST
SNSS: 2.28 (+0.01)
Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting
GlobeNewswire - Mon Dec 08, 12:30PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The results will be presented today in an oral session titled "Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Drugs II" taking place from 10:30 AM to 12:00 PM PT at the 56 American Society of Hematology Annual Meeting in San Francisco, California. The presentation (abstract 385, Gateway Ballroom 103), titled "Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)," is available at www.sunesis.com.
SNSS: 2.28 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST
LGCY: 13.35 (+0.51), PFIE: 2.60 (-0.06), MCEP: 6.29 (+0.12), MDGN: 7.13 (-0.75), LQDT: 9.52 (+0.09), AXPW: 0.39 (-0.04), PRTK: 26.95 (+0.65), BSI: 2.97 (+0.02), DRIV: 25.99 (+0.06), CBST: 101.94 (+0.14), QTWW: 2.96 (-0.04), CALA: 16.11 (+0.62), MPO: 1.00 (-0.02), SNSS: 2.28 (+0.01), CTP: 6.53 (+0.13), LPX: 17.44 (+0.42), SAEX: 3.75 (+0.50), DRYS: 1.01 (+0.02), VPCO: 1.02 (+0.01), XLRN: 38.02 (+0.07)
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 90.70 (+0.93), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), SNSS: 2.28 (+0.01), AGIO: 118.55 (+0.11), BMY: 60.04 (+0.56), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Sunesis Spin Doctor Tiptoes Around Failed Leukemia Drug Trial
at The Street - Sun Dec 07, 4:28PM CST
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
SNSS: 2.28 (+0.01)
Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:30AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented on Tuesday, December 9, at 8:45 AM Pacific Time in the "Late Breaking Abstracts" session of the 56 American Society of Hematology Annual Meeting in San Francisco, California. The presentation (abstract LBA-6, North Building, Hall D), titled "Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)," will be available on the Sunesis website at www.sunesis.com following the ASH presentation.
SNSS: 2.28 (+0.01)
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
at The Street - Tue Dec 02, 10:00AM CST
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
AGEN: 5.03 (-0.01), BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CYTR: 2.96 (+0.23), SNSS: 2.28 (+0.01), CTIC: 2.23 (-0.02), NVS: 102.20 (-0.17)
Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting
GlobeNewswire - Tue Dec 02, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9, 2014 at 10:30 AM Pacific Time to discuss the presentation of results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML), as well as an MD Anderson Cancer Center-sponsored Phase 1/2 study of vosaroxin and decitabine in newly diagnosed older patients with AML and high risk myelodysplastic syndrome, at the 56th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9 in San Francisco, California.
SNSS: 2.28 (+0.01)
Today In SA PRO: Monday, December 1
SA PRO Top Ideas - at Seeking Alpha - Tue Dec 02, 4:00AM CST
Top Idea: Cooper-Standard by Alpha Gen Capital: Long / Small-Cap / Auto Parts / GARP / Margin Expansion / Market Share Growth / Underfollowed / 40% Upside Top Idea: Home Loan Servicing Solutions by Moses Li, Mikhail Stepanov, and Shaun Raja:...
VTNR: 3.55 (+0.25), CPS: 54.36 (-0.13), SNSS: 2.28 (+0.01), LE: 35.84 (+0.19), HLSS: 16.15 (-0.14)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 2.13 (+0.18), AMRN: 1.18 (unch), JCP: 8.05 (+0.14), SNSS: 2.28 (+0.01), SWHC: 12.63 (-0.20)
Announcing This Week's Outstanding Performance Award Winners - New Capital And EnhydrisPECorp
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Dec 01, 4:00AM CST
Dear readers, Seeking Alpha has been paying contributors for exclusive content since 2011. We launched SA PRO two years ago, on the Monday after Thanksgiving 2012, with the dual aim of creating a premium subscription product for interested readers...
SNSS: 2.28 (+0.01), LE: 35.84 (+0.19)
Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology
GlobeNewswire - Mon Nov 24, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of results from the Company's REVEAL-1 (Response Evaluation of Vosaroxin in Elderly AmL) trial, a Phase 2 trial of single agent vosaroxin in previously untreated, poor-risk elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy, in the November 17, 2014 Online Version of Record of the British Journal of Haematology. The article, titled "REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukemia," is available online at http://onlinelibrary.wiley.com/doi/10.1111/bj...4/abstract.
SNSS: 2.28 (+0.01)
Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica
GlobeNewswire - Wed Nov 19, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the online publication of results from the Company's Phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) in the November 7, 2014 Ahead of Print issue of Haematologica. The article, titled "A Phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia," is available online at http://www.haematologica.org/content/early/recent.
SNSS: 2.28 (+0.01)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 101.90 (+1.10), FB: 75.74 (-0.49), GERN: 3.03 (unch), DNDN: 0.13 (-0.02), SNSS: 2.28 (+0.01), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), GRPN: 7.97 (+0.51), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), RFMD: 16.59 (-0.35)
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:25AM CST
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 391.66 (-0.45), SNSS: 2.28 (+0.01), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
